Progression from tuberculosis to multi drug resistance-TB in revised national tuberculosis control programme: perspectives from health system care givers
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20192091Keywords:
MDR-TB, RNTCP, PMDT-guidelines 2016Abstract
Background: The aims and objectives were to study the progression from tuberculosis to multi drug resistance-TB in revised national tuberculosis control programme: perspectives from health system care givers.
Methods: The study was carried out in TB Sanatorium ITKI, Sadar Hospital Ranchi and RIMS Ranchi. The interview of various health personnel including SAHIYAs was taken using a semi-structured questionnaire based on programmatic management of multi drug resistant tuberculosis guidelines -2016.
Results: Among Doctors knowledge level was good compared to other health personnel which had mean value 7.33 (±2.79), laboratory technician 3.45 (±2.64), STS 4.67 (±1.59), Sahiya 2.1 (±0.73). Regarding capacity enhancement level all health personnel needed refresher trainings in which doctors got 4.67 (±1.58), laboratory technician 3.45±2.64, STS 1.72±0.34, and Sahiya 0.5±0.52. Specially sahiya needs training regarding MDR-TB because they are the connecting link between health system and community. Regarding execution level, Doctors got 1.86 (±0.74), laboratory technician 1.64 (±0.56), STS 1.64 (±0.56) and Sahiya (ASHA) 2.2 (±0.44). Sahiya were better than other health personnel at execution level.
Conclusions: Advocacy, communication, and social mobilization are important aspects of TB control, Policy makers and administrators should be sensitized for need of adequate and sustained funding for TB control to ensure quality capacity building. They need to provide continuous and quality training of staff at different levels and retention of trained staff and periodic reviews to identify gaps and take corrective steps.
Metrics
References
WHO (2017). Global TB Report. World Health Organization, Geneva, 2018.
WHO (2018). Global TB Report. World Health Organization, Geneva, 2017.
Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet. 1998,352:1886-91.
Santha T, Garg R, Frieden TR, Chandrasekaran V, Subramani R, Gopi PG, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS program in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis. 2002;6:780-8.
Xu W, Lu W, Zhou Y, Zhu L, Shen H, Wang J. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res. 2009;9:169.
Chadha SS, Sharath BN, Reddy K, Jaju J, Vishnu PH, Rao S, et al. Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. PLoS One. 2011;6(11):e26659.
Margaret C. Director-General of the World Health Organization. 2009. MDR-TB: overcoming resistance is essential. Opening remarks at the panel on “Funding and implementing innovation”, 2009 Pacific Health Summit. Seattle, Washington, USA, 2009.
Stop TB Partnership and World Health Organization, Geneva. Global PlantoStop TB 2006–2015.
Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis. 2009;13:1154–60.
World Health Organisation, Geneva. Multidrug and extensively drug-resistant TB (M/XDR-TB). 2010. Global Report on Surveillance and Response (WHO/HTM/TB/2010.3), 2010.
Central Tuberculosis Division. 2010. DOTS Plus Guidelines, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2010.
Govt. of India, TB India 2008, RNTCP status report,I am stopping TB, Ministry of health and family Welfare, New Delhi, 2008.
Tb and HIV Coinfection, Statistics, diagnosis and treatment : Assessed on 2nd April 2019 available on https://www.tbfacts.org/tb-hiv/
Levin AC, Gums JG, Grauer K Tuberculosis. The primary care physician's role in eradication. Postgrad Med. 1993;93(3):46-60.
Central TB Division, New Delhi: Operational Guidelines for Senior Treatment Supervisors, Part-l, Ensuring proper treatment; Ministry of Health & Family Welfare, Directorate General of Health Services, New Delhi, 2002: 27.
Press Information Bureau: Ministry of Health and Family Welfare, Involvement of Asha to combat TB, 2012.
Conference Paper, Conference : World Conference on Infectious Disease-2013, Chennai, Tamil Nadu, India, 18th - 22nd December 2013, Banuru Prasad, ASHA’s Role in Tuberculosis Control Programme, 2013.
Treatment of Drug Resistant TB. WHO, 2019.
Chatterjee S, Poonawala H, Jain Y Drug-resistant tuberculosis: is India ready for the challenge? BMJ Global Health. 2018;3:e000971.
Dheda K, Umbo T, Maartens G. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5:291–360.
Law S, Piatek AS, Vincent C. Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. Lancet Public Health. 2017;2:47–55.
Parmar MM, Sachdeva KS, Rade K, Ghedia M, Bansal A, Nagaraja SB, et al. Airborne infection control in India: baseline assessment of health facilities. Indian J Tuberc. 2015;62:2117.
Manson AL, Abeel T, Galagan JE, Sundaramurthi JC, Salazar A, Gehrmann T, et al. Mycobacterium tuberculosis Whole Genome Sequences From Southern India Suggest Novel Resistance Mechanisms and the Need for Region-Specific Diagnostics. Clin Infect Dis. 2017;64(11):1494-501.
Stagg HR, Lipman MC, McHugh TD, Jenkins HE. Isoniazid-resistant tuberculosis: a cause for concern? Int J Tuberc Lung Dis. 2017;21(2):129-139.
Chatterjee S, Poonawala H, Jain Y. Drug-resistant tuberculosis: is India ready for the challenge? BMJ Global Health. 2018;3:e000971.
The NIAID tuberculosis research strategic plan working group, 2018. TB research strategic plan, 2018.
Workicho A, Kassahun W, Alemseged F. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study. Infect Drug Resist. 2017;10:91-6.
Downloads
Published
How to Cite
Issue
Section
